arrow
M

Miguel-Angel Perales

Memorial Sloan Kettering Cancer Center
H指数:91
被引数:3.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant

移植物抗宿主病预防措施塑造造血细胞移植后的T细胞生物学和免疫重建

2026-10-210
PRE
Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

免疫效应细胞相关神经毒性综合征的预测因素和结局:接受嵌合抗原受体T细胞治疗侵袭性B细胞非霍奇金淋巴瘤患者的分析

2026-10-210
PRE
A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Myeloablative Conditioning in Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation

一项关于浓缩白消安、美法仑和氟达拉滨骨髓清除性预处理在体外CD34⁺选择的同种异基因造血细胞移植中的初步研究

2026-10-150
PRE
Itacitinib plus calcineurin inhibitor–based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 results

伊塔西替尼联合钙调神经磷酸酶抑制剂为基础的治疗预防移植物抗宿主病:GRAVITAS-119研究结果

2026-10-070
PRE
Sugar-rich foods exacerbate antibiotic-induced microbiome disruption

高糖食物加剧抗生素诱导的微生物组紊乱

Nature
IF48.5
2026-09-300
OAAI
Multi-Criteria Decision Analysis using Physician Preferences from a Global Discrete Choice Experiment to Investigate the Selection of Preemptive Antiviral Treatments for Post-Hematopoietic Cell Transplant Cytomegalovirus Infection

基于全球离散选择实验中医生偏好的多准则决策分析,以研究造血细胞移植后巨细胞病毒感染的抢先抗病毒治疗方案选择

2026-09-010
OAAI
Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis

CD19嵌合抗原受体T细胞疗法后出现的迟发性血细胞减少:细胞治疗联盟的分析

2026-06-260
OA
Safety and Outcomes of CD19 CAR-T Cell Therapy in Splenectomized Patients With B-Cell Lymphomas

脾切除的B细胞淋巴瘤患者中CD19 CAR-T细胞疗法的 safety 和 outcomes

2026-06-260
PRE
Tuberculosis After Allogeneic Hematopoietic Cell Transplant: A 15-Year Case Series Highlighting Diagnostic Challenges

异基因造血细胞移植后的结核病:一项突出诊断挑战的15年病例系列研究

2026-06-090
PRE
Expert Panel Review and Practical Guidance on Biomarker Testing With Engineered Immune Effector Cells

专家小组评审及工程化免疫效应细胞生物标志物检测的实用指南

2026-05-160
OAAI
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations

TP53突变携带的髓系恶性肿瘤中,移植后干预和慢性移植物抗宿主病对生存的影响

2026-04-120
PRE
Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles

推进实体瘤细胞疗法:克服生物学、操作和监管障碍的途径

2026-02-260
PRE
CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

CXCL9作为一种新型预后标志物,用于识别患有噬血细胞性淋巴组织细胞增多症的成人高风险群体。

Blood
IF23.1
2026-02-263
PRE
Outcomes of terminal complement blockade in adults with high-risk transplant-associated thrombotic microangiopathy: a comparative analysis

高危移植相关血栓性微血管病成人中终末补体阻滞的结局:一项比较分析

2025-11-280
PRE